Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Notorious KRAS: Taking down cancer researchers’ biggest foe

After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?

by Lisa M. Jarvis
September 23, 2019 | A version of this story appeared in Volume 97, Issue 37
A crystal structure of KRAS G12C with the chemical structure of Amgen's AMG 510 tucked into a pocket.

Credit: Will Ludwig/C&EN/Amgen | Amgen's AMG 510, shown here bound to its protein target, was the first KRAS G12C inhibitor to be tested in humans.

Article:

This article has been sent to the following recipient: